Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 55

Sort by

Sort Order Select

Journal Articles

Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial

Blood (2022) 140 (2): 112–120.

https://doi.org/10.1182/blood.2021014960

Published: 2022

Includes: Supplemental data

Journal Articles

Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib

Blood (2021) 138 (26): 2810–2827.

https://doi.org/10.1182/blood.2020010146

Published: 2021

Includes: Supplemental data

Journal Articles

Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables

Andrew W. Roberts, Shuo Ma, Thomas J. Kipps, Steven E. Coutre, Matthew S. Davids, Barbara Eichhorst, Michael Hallek, John C. Byrd, Kathryn Humphrey, Lang Zhou, Brenda Chyla, Jacqueline Nielsen, Jalaja Potluri, Su Young Kim, Maria Verdugo, Stephan Stilgenbauer, William G. Wierda, John F. Seymour

Blood (2019) 134 (2): 111–122.

https://doi.org/10.1182/blood.2018882555

Published: 2019

Includes: Supplemental data

Journal Articles

Incidence of and Risk Factors for Major Hemorrhage in Patients Treated with Ibrutinib: Results from an Integrated Analysis

Blood (2017) 130 (Supplement 1): 1743.

https://doi.org/10.1182/blood.V130.Suppl_1.1743.1743

Published: 2017

Journal Articles

Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT

Christine E. Ryan, Bita Sahaf, Aaron C. Logan, Susan O’Brien, John C. Byrd, Peter Hillmen, Jennifer R. Brown, Martin J. S. Dyer, Anthony R. Mato, Michael J. Keating, Samantha Jaglowski, Fong Clow, Andrew R. Rezvani, Lori Styles, Steven E. Coutre, David B. Miklos

Blood (2016) 128 (25): 2899–2908.

https://doi.org/10.1182/blood-2016-06-715284

Published: 2016

Includes: Supplemental data

Journal Articles

A Retrospective Analysis of Pneumocystis Jirovecii Pneumonia Infection in Patients Receiving Idelalisib in Clinical Trials

Laurie H Sehn, MD, Michael Hallek, Wojciech Jurczak, Jennifer R. Brown, Paul M. Barr, John Catalano, Steven E. Coutre, MD, Richard R. Furman, Nicole Lamanna, Ysebaert Loïc, Andrew D. Zelenetz, Jeffrey P. Sharman, Sven DeVos, Adeboye Henry Adewoye, Yeonhee Kim, Ian W. Flinn, MD PhD, Gilles A. Salles

Blood (2016) 128 (22): 3705.

https://doi.org/10.1182/blood.V128.22.3705.3705

Published: 2016

Journal Articles

Analysis of an Online Decision Support Tool for Chronic Lymphocytic Leukemia: Disparities in Treatment Selection Between Experts and Community Practitioners

Kristen M Rosenthal, PhD, Farrukh T. Awan, Jacqueline C. Barrientos, MD, Steven E. Coutre, MD, Kevin L Obholz, PhD, Andrew D. Zelenetz, MD PhD

Blood (2016) 128 (22): 5958.

https://doi.org/10.1182/blood.V128.22.5958.5958

Published: 2016

Journal Articles

Five-Year Experience with Single-Agent Ibrutinib in Patients with Previously Untreated and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia

Susan M. O'Brien, MD, Richard R. Furman, MD, Steven E. Coutre, MD, Ian W. Flinn, MD PhD, Jan Burger, MD PhD, Kristie Blum, MD, Jeff Sharman, MD, William G. Wierda, MD PhD, Jeffrey Jones, MD MPH, Weiqiang Zhao, MD PhD, Nyla A. Heerema, PhD, Amy J. Johnson, PhD, Ying Luan, PhD, Danelle F. James, MD MAS, Alvina D. Chu, MD, John C. Byrd, MD

Blood (2016) 128 (22): 233.

https://doi.org/10.1182/blood.V128.22.233.233

Published: 2016

Journal Articles

ATRA, Arsenic Trioxide (ATO), and Gemtuzumab Ozogamicin (GO) Is Safe and Highly Effective in Patients with Previously Untreated High-Risk Acute Promyelocytic Leukemia (APL): Final Results of the SWOG/Alliance/ECOG S0535 Trial

Jeffrey E. Lancet, MD, Anna Moseley, Rami S Komrokji, MD, Steven E. Coutre, MD, Daniel J. DeAngelo, MD PhD, Martin S. Tallman, MD, Mark Litzow, MD, Megan Othus, Frederick R Appelbaum, MD

Blood (2016) 128 (22): 896.

https://doi.org/10.1182/blood.V128.22.896.896

Published: 2016

Journal Articles

Outcomes of Ibrutinib Therapy By Age in Patients with CLL/SLL: Analyses from Phase 3 Trial Data (RESONATE and RESONATE-2)

Jennifer A. Woyach, MD, Peter Hillmen, Jennifer R. Brown, MD PhD, Steven E. Coutre, MD, Paul Barr, MD, Susan M. O'Brien, MD, Jacqueline C. Barrientos, MD, Stephen Devereux, PhD FRCP, FRCPath, Neil E. Kay, MD, Nishitha Reddy, MD MSCI, MBBS, Stephen Mulligan, MBBS, MD FRACP, FRCPA, Alessandra Tedeschi, Cathy Zhou, MS, Joi Ninomoto, PharmD, Danelle F. James, MD MAS, John C. Byrd, MD, Jan Burger, MD PhD

Blood (2016) 128 (22): 2041.

https://doi.org/10.1182/blood.V128.22.2041.2041

Published: 2016

Journal Articles

11q Deletion (del11q) Is Not a Prognostic Factor for Adverse Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Ibrutinib: Pooled Data from 3 Randomized Phase 3 Studies

Blood (2016) 128 (22): 2042.

https://doi.org/10.1182/blood.V128.22.2042.2042

Published: 2016

Journal Articles

Venetoclax (VEN) Monotherapy for Patients with Chronic Lymphocytic Leukemia (CLL) Who Relapsed after or Were Refractory to Ibrutinib or Idelalisib

Jeffrey Jones, Michael Y. Choi, MD, Anthony R. Mato, Richard R. Furman, Matthew S. Davids, Leonard T. Heffner, MD, Bruce D. Cheson, Nicole Lamanna, MD, Paul M. Barr, Herbert Eradat, Ahmad Halwani, Brenda Chyla, Ming Zhu, Maria Verdugo, Rod A. Humerickhouse, MD, Jalaja Potluri, William G. Wierda, MD PhD, Steven E. Coutre, MD

Blood (2016) 128 (22): 637.

https://doi.org/10.1182/blood.V128.22.637.637

Published: 2016

Journal Articles

Comparable Outcomes of Patients Eligible Versus Ineligible for Southwest Oncology Group (SWOG) Leukemia Studies

Abby Statler, MPH, MA, Megan Othus, PhD, Harry P. Erba, MD PhD, Thomas R. Chauncey, MD PhD, Jerald P. Radich, MD, Steven E. Coutre, MD, Anjali S. Advani, MD, Sucha Nand, MD, Farhad Ravandi, MD, Sudipto Mukherjee, MD, PhD, M.P.H., Mikkael A. Sekeres, MD MS

Blood (2016) 128 (22): 4002.

https://doi.org/10.1182/blood.V128.22.4002.4002

Published: 2016

Journal Articles

A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia

Susan M. O'Brien, Nicole Lamanna, Thomas J. Kipps, Ian Flinn, Andrew D. Zelenetz, Jan A. Burger, Michael Keating, Siddhartha Mitra, Leanne Holes, Albert S. Yu, David M. Johnson, Langdon L. Miller, Yeonhee Kim, Roger D. Dansey, Ronald L. Dubowy, Steven E. Coutre

Blood (2015) 126 (25): 2686–2694.

https://doi.org/10.1182/blood-2015-03-630947

Published: 2015

Includes: Supplemental data

Journal Articles

Marqibo®, Vincristine Sulfate Liposome Injection, for the Treatment of Advanced, Relapsed or Refractory Philadelphia Chromosome-Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) in an Adolescent Young Adult (AYA) Population

Gary J Schiller, MD, Lloyd E. Damon, MD, Wendy Stock, MD, Steven E Coutre, MD, Pamela Hsu, Lucy Prasad, Dan Douer, MD

Blood (2015) 126 (23): 1291.

https://doi.org/10.1182/blood.V126.23.1291.1291

Published: 2015

Journal Articles

Ibrutinib-Associated Rash: Single-Center Experience of Clinicopathologic Features and Management

David J Iberri, MD, Bernice Kwong, MD, Laurel Stevens, MD, Steven E Coutre, MD, Jinah Kim, MD PhD, Jean Sabile, BS, Ranjana H Advani, MD

Blood (2015) 126 (23): 4860.

https://doi.org/10.1182/blood.V126.23.4860.4860

Published: 2015

Journal Articles

Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib

John C. Byrd, Richard R. Furman, Steven E. Coutre, Jan A. Burger, Kristie A. Blum, Morton Coleman, William G. Wierda, Jeffrey A. Jones, Weiqiang Zhao, Nyla A. Heerema, Amy J. Johnson, Yun Shaw, Elizabeth Bilotti, Cathy Zhou, Danelle F. James, Susan O'Brien

Blood (2015) 125 (16): 2497–2506.

https://doi.org/10.1182/blood-2014-10-606038

Published: 2015

Includes: Supplemental data

Journal Articles

Update on a Phase 2 Study of Idelalisib in Combination with Rituximab in Treatment-Naïve Patients ≥65 Years with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Susan O'Brien, Nicole Lamanna, MD, Thomas J. Kipps, MD PhD, Ian W. Flinn, MD PhD, Andrew D. Zelenetz, MD PhD, Jan A. Burger, MD PhD, Leanne M. Holes, Yoonjin Cho, PhD, Ronald L. Dubowy, MD, Steven E. Coutre, MD

Blood (2014) 124 (21): 1994.

https://doi.org/10.1182/blood.V124.21.1994.1994

Published: 2014

Journal Articles

Durable Responses Following Treatment with the PI3K-Delta Inhibitor Idelalisib in Combination with Rituximab, Bendamustine, or Both, in Recurrent Indolent Non-Hodgkin Lymphoma: Phase I/II Results

Sven de Vos, MD PhD, Nina D. Wagner-Johnston, MD, Steven E. Coutre, MD, Ian Flinn, Marshall T. Schreeder, MD, Nathan Fowler, MD, Jeff P. Sharman, MD, Ralph V. Boccia, MD, Jaqueline C. Barrientos, MD, Kanti R. Rai, MD, Thomas E Boyd, MD, Richard R. Furman, MD, Leanne M. Holes, Yeonhee Kim, PhD, Wayne R. Godfrey, MD, John P. Leonard, MD

Blood (2014) 124 (21): 3063.

https://doi.org/10.1182/blood.V124.21.3063.3063

Published: 2014

Journal Articles

Second Interim Analysis of a Phase 3 Study of Idelalisib (ZYDELIG ® ) Plus Rituximab (R) for Relapsed Chronic Lymphocytic Leukemia (CLL): Efficacy Analysis in Patient Subpopulations with Del(17p) and Other Adverse Prognostic Factors

Blood (2014) 124 (21): 330.

https://doi.org/10.1182/blood.V124.21.330.330

Published: 2014

NARROW

Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial

Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib

Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables

Incidence of and Risk Factors for Major Hemorrhage in Patients Treated with Ibrutinib: Results from an Integrated Analysis

Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT

A Retrospective Analysis of Pneumocystis Jirovecii Pneumonia Infection in Patients Receiving Idelalisib in Clinical Trials

Analysis of an Online Decision Support Tool for Chronic Lymphocytic Leukemia: Disparities in Treatment Selection Between Experts and Community Practitioners

Five-Year Experience with Single-Agent Ibrutinib in Patients with Previously Untreated and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia

ATRA, Arsenic Trioxide (ATO), and Gemtuzumab Ozogamicin (GO) Is Safe and Highly Effective in Patients with Previously Untreated High-Risk Acute Promyelocytic Leukemia (APL): Final Results of the SWOG/Alliance/ECOG S0535 Trial

Outcomes of Ibrutinib Therapy By Age in Patients with CLL/SLL: Analyses from Phase 3 Trial Data (RESONATE and RESONATE-2)

11q Deletion (del11q) Is Not a Prognostic Factor for Adverse Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Ibrutinib: Pooled Data from 3 Randomized Phase 3 Studies

Venetoclax (VEN) Monotherapy for Patients with Chronic Lymphocytic Leukemia (CLL) Who Relapsed after or Were Refractory to Ibrutinib or Idelalisib

Comparable Outcomes of Patients Eligible Versus Ineligible for Southwest Oncology Group (SWOG) Leukemia Studies

A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia

Marqibo®, Vincristine Sulfate Liposome Injection, for the Treatment of Advanced, Relapsed or Refractory Philadelphia Chromosome-Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) in an Adolescent Young Adult (AYA) Population

Ibrutinib-Associated Rash: Single-Center Experience of Clinicopathologic Features and Management

Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib

Update on a Phase 2 Study of Idelalisib in Combination with Rituximab in Treatment-Naïve Patients ≥65 Years with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Durable Responses Following Treatment with the PI3K-Delta Inhibitor Idelalisib in Combination with Rituximab, Bendamustine, or Both, in Recurrent Indolent Non-Hodgkin Lymphoma: Phase I/II Results

Second Interim Analysis of a Phase 3 Study of Idelalisib (ZYDELIG ® ) Plus Rituximab (R) for Relapsed Chronic Lymphocytic Leukemia (CLL): Efficacy Analysis in Patient Subpopulations with Del(17p) and Other Adverse Prognostic Factors

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only